Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 10/20 | 0.54 |
| ▸ | CA2 | P00918 | 10/20 | 0.54 |
| ▸ | CA9 | Q16790 | 10/20 | 0.54 |
| ▸ | CA12 | O43570 | 9/20 | 0.54 |
| ▸ | CA4 | P22748 | 9/20 | 0.54 |
| ▸ | CA5A | P35218 | 9/20 | 0.54 |
| ▸ | CA7 | P43166 | 9/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100894 | 0.93 | TDP1 (0.66) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL28383839 | 0.86 | MAOB (0.47) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL28460825 | 0.81 | MAOB (0.50) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL561190 | 0.80 | L3MBTL1 (1.00) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL8804099 | 0.79 | CA1 (0.58) | TDP1L3MBTL1CA1CA2CA9 | |
| Carbon Monoxide SCHEMBL6562620 | 0.79 | L3MBTL1 (0.87) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL8804107 | 0.79 | MAOB (0.47) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL30525949 | 0.77 | KDM4E (0.50) | CA1CA2CA9MAOBTSHR | |
| SCHEMBL8804102 | 0.77 | MAOB (0.46) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL9164159 | 0.77 | TDP1 (0.83) | TDP1L3MBTL1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3856164-B1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3856164-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | Achillion Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-112996497-A | Morphic forms of complement factor D inhibitors | 艾其林医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020069024-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | TDP1 3420/4885L3MBTL1 76/4885CA1 4068/4885 |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | CFD, CFH, CFB | TDP1 4078/4885L3MBTL1 2894/4885CA1 4405/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | TDP1 3681/4885L3MBTL1 135/4885CA1 3497/4885 |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | TDP1 4078/4885L3MBTL1 2894/4885CA1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.